ABSTRACT
We evaluated antitumor efficacy of photodynamic therapy of murine Ehrlich carcinoma and rat sarcoma M-1 with new photosensitizers 131-N-(4-aminobutyl)amydo chlorine e6 (1), 132-(5-guanidylbutanamido)-chlorine e6 (2), and 132-(5-biguanidylbutanamido)-chlorine e6 (3). The inhibiting effect of the photodynamic therapy was evaluated by the following parameters: tumor growth inhibition, complete regression of the tumors, and absolute growth rate of the tumor nodes in animals with the continued neoplasia growth. The criterion of cure was the absence of tumors up to 90 days after the therapy. It is shown that the studied photosensitizers have high antitumor activity in the photodynamic therapy of the Ehrlich carcinoma and sarcoma M-1.
Subject(s)
Carcinoma , Photochemotherapy , Porphyrins , Mice , Animals , Photosensitizing Agents/pharmacology , Photosensitizing Agents/therapeutic use , Guanidine , Guanidines , Carcinoma/drug therapy , Animals, Laboratory , Porphyrins/pharmacologyABSTRACT
The efficacy of a new photosensitizer of chlorin E6 conjugated with a prostate-specific membrane antigen (PSMA) in photodynamic therapy of murine melanoma B16 was studied in in vivo experiments. The dynamics of photosensitizer accumulation in the tumor and surrounding tissues was evaluated and antitumor efficacy of photodynamic therapy was assessed by parameters of regression and morphological characteristics of experimental transplanted melanoma B16. The inhibitory effect of photodynamic therapy on melanoma was evaluated by complete regression of the tumor, absolute tumor growth coefficient in animals with continuation of tumor growth, and the increase in life span in comparison with the control; the criterion of cure was the absence of signs of tumor recurrence in mice within 90 days after therapy. The therapeutic potential of photodynamic therapy was determined by devitalization of tumor cells (histological examination of the zones of laser exposure on day 21 after treatment). The photosensitizer with PSMA-ligand exhibited high antitumor activity in photodynamic therapy for melanoma B16. Photodynamic therapy carried out at the optimum time after photosensitizer injection with experimentally determined parameters of laser exposure allows achieving the maximum inhibitory effect on melanoma. Pathomorphological study in the zones of exposure detected no survived tumor cells.
Subject(s)
Chlorophyllides/therapeutic use , Melanoma, Experimental/drug therapy , Photochemotherapy/methods , Skin Neoplasms/drug therapy , Urea/analogs & derivatives , Animals , Cell Line, Tumor , Chlorophyllides/chemistry , Chlorophyllides/pharmacokinetics , Female , Ligands , Melanoma, Experimental/diagnostic imaging , Melanoma, Experimental/metabolism , Melanoma, Experimental/pathology , Mice , Mice, Inbred C57BL , Neoplasm Recurrence, Local/diagnosis , Neoplasm Recurrence, Local/metabolism , Neoplasm Recurrence, Local/pathology , Photosensitizing Agents/chemistry , Photosensitizing Agents/pharmacokinetics , Photosensitizing Agents/therapeutic use , Skin Neoplasms/diagnostic imaging , Skin Neoplasms/metabolism , Skin Neoplasms/pathology , Urea/chemistry , Urea/pharmacokinetics , Urea/therapeutic useABSTRACT
We studied the effectiveness of photodynamic therapy with the photosensitizer Photoran E6 on the model of rat sarcoma M-1 positive for mutant p53 gene. Experiments showed that Photoran E6 exhibits high antitumor activity in photodynamic therapy of solid tumor of the connective tissue. Photodynamic therapy carried out during the optimal period after injections of Photoran E6 with the determined parameters of laser exposure allows achieving the maximum inhibitory effect on sarcoma M-1: 100% cured animals. Immunohistochemical study revealed no live tumor cells with expression of the mutant p53 protein in areas of photodynamic exposure.
Subject(s)
Photochemotherapy/methods , Photosensitizing Agents/therapeutic use , Sarcoma/therapy , Animals , Immunohistochemistry , Rats , Tumor Suppressor Protein p53/metabolismABSTRACT
A method for photodynamic therapy was developed in experiments on the model of melanoma B16. The photosensitizer is injected by two doses, while laser exposure is carried out during coincidence of its maximum accumulation phases in tumor vessels and cells. This method increased the percentage of animals with complete regression of the tumor, decreased the coefficient of absolute tumor increase in animals with progressive tumor growth, increased survival of mice, and significantly decreased melanoma metastasizing to the lungs in comparison with untreated animals and even with the standard photodynamic therapy.
Subject(s)
Lasers , Melanoma/therapy , Photochemotherapy/methods , Animals , Disease Models, Animal , MiceABSTRACT
The role of different laser energy densities used in photodynamic therapy in the reparation of radiation ulcers caused by X-ray exposure in a dose of 80 Gy was studied. Tissue reparation manifested differently at different laser energy densities. After photodynamic therapy at energy density of 0.1 J/cm2 the rate of healing was notably higher during early periods. After exposure at 5 and 40 J/cm2 acceleration of ulcer healing was observed 14 and more days after the treatment, indicating the emergence of another mechanism of photodynamic therapy effect. Laser energy density of 5 J/cm2 was the most effective for maximally complete healing of radiation ulcers.
Subject(s)
Photochemotherapy/methods , Radiation Injuries/therapy , Skin/radiation effects , Animals , Dose-Response Relationship, Radiation , Female , Laser Therapy/methods , Lasers , Rats , Time Factors , Wound Healing , X-RaysABSTRACT
An experimental treatment with rose bengal showed that optimal effectiveness of photodynamic therapy of sarcoma M-1 was achieved 3-4 hr after intraperitoneal injection of 10 mg/kg body.